Multidisciplinary treatment of advanced ALK-positive squamous cell lung carcinoma

VernacularTitle:1例晚期ALK阳性肺鳞癌多学科临床决策探讨
Author: Wu TIANYUE ¹ ; Guo YAOYANG ; Pan ZHANYU ; Jiang ZHANSHENG
Author Information

1. 天津医科大学肿瘤医院中西医结合科,国家肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室(天津市 300060)
Keywords: ALK fusion; advanced lung squamous cell carcinoma; lorlatinib; multidisciplinary team(MDT)
From: Chinese Journal of Clinical Oncology 2024;51(12):616-621
CountryChina
Language:Chinese
Abstract: Anaplastic lymphoma kinase(ALK)fusion is commonly observed in lung adenocarcinoma,with an incidence rate of 5%-7%.Due to the tumor heterogeneity in advanced non-small cell lung cancer,ALK fusion can also occur in lung squamous cell carcinoma.A mul-tidisciplinary team(MDT)combines various professional opinions and evidence-based medical principles to provide personalized treatment recommendations,particularly for complex cases.This study presents the MDT diagnostic and treatment approach for a patient with lung squamous cell carcinoma with an ALK mutation.Following initial diagnosis at stage ⅢB,the patient exhibited rapid disease progression with liver and brain metastases after sequence chemoradiotherapy.After genetic testing revealed ALK fusion,the patient was treated with the ALK inhibitor,lorlatinib,which resulted in tumor regression and a persistent partial response.